Next Science Ltd
ASX:NXS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.125
0.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Next Science Ltd
Operating Margin
Next Science Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | AU |
| Market Cap | 39.4m AUD |
| Operating Margin |
-58%
|
| Country | JP |
| Market Cap | 6.8T JPY |
| Operating Margin |
28%
|
| Country | CH |
| Market Cap | 37.9B CHF |
| Operating Margin |
13%
|
| Country | DK |
| Market Cap | 200.9B DKK |
| Operating Margin |
27%
|
| Country | US |
| Market Cap | 16.9B USD |
| Operating Margin |
17%
|
| Country | KR |
| Market Cap | 9.9T KRW |
| Operating Margin |
-245%
|
| Country | CA |
| Market Cap | 6.9B USD |
| Operating Margin |
4%
|
| Country | CN |
| Market Cap | 48.6B CNY |
| Operating Margin |
46%
|
| Country | US |
| Market Cap | 6.3B USD |
| Operating Margin |
32%
|
| Country | US |
| Market Cap | 6.1B USD |
| Operating Margin |
12%
|
| Country | UK |
| Market Cap | 4.8B GBP |
| Operating Margin |
13%
|
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Next Science Ltd's most recent financial statements, the company has Operating Margin of -58.2%.
You don't have any saved screeners yet
